Best PLR Content Marketing Tokelau: September 2016

Friday, September 30, 2016

Adocef

Adocef may be available in the countries listed below.

Ingredient matches for Adocef

Cefadroxil

Cefadroxil is reported as an ingredient of Adocef in the following countries:

Bangladesh

International Drug Name Search

Guaifenesin/Pseudoephedrine Controlled-Release Capsules

Pronunciation: gwye-FEN-ah-sin/sue-do-eh-FED-rin
Generic Name: Guaifenesin/Pseudoephedrine
Brand Name: Examples include Entex PSE and Nalex CR

Guaifenesin/Pseudoephedrine Controlled-Release Capsules are used for:

Relieving congestion, cough, and throat and airway irritation due to colds, flu, or hay fever. It may also be used for other conditions as determined by your doctor.

Guaifenesin/Pseudoephedrine Controlled-Release Capsules are a decongestant and expectorant combination. It works by constricting blood vessels, reducing swelling in the nasal passages, and thinning and loosening mucus in the airway. This allows you to breathe more easily and makes coughs more productive.

Do NOT use Guaifenesin/Pseudoephedrine Controlled-Release Capsules if:

you are allergic to any ingredient in Guaifenesin/Pseudoephedrine Controlled-Release Capsules

you have severe high blood pressure, rapid heartbeat, or other severe heart problems (eg, heart blood vessel disease)

you have taken furazolidone or a monoamine oxidase (MAO) inhibitor (eg, phenelzine) within the last 14 days

Contact your doctor or health care provider right away if any of these apply to you.

Before using Guaifenesin/Pseudoephedrine Controlled-Release Capsules:

Some medical conditions may interact with Guaifenesin/Pseudoephedrine Controlled-Release Capsules. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

if you are pregnant, planning to become pregnant, or are breast-feeding

if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

if you have allergies to medicines, foods, or other substances

if you have a fast, slow, or irregular heartbeat

if you have a history of adrenal gland problems (eg, tumor), heart problems, high blood pressure, diabetes, heart blood vessel problems, stroke, glaucoma, an enlarged prostate, seizures, or an overactive thyroid

if you have chronic cough

Some MEDICINES MAY INTERACT with Guaifenesin/Pseudoephedrine Controlled-Release Capsules. Tell your health care provider if you are taking any other medicines, especially any of the following:

Beta-blockers (eg, propranolol), COMT inhibitors (eg, tolcapone), furazolidone, indomethacin, MAO inhibitors (eg, phenelzine), or tricyclic antidepressants (eg, amitriptyline) because they may increase the risk of Guaifenesin/Pseudoephedrine Controlled-Release Capsules's side effects

Digoxin or droxidopa because the risk of irregular heartbeat or heart attack may be increased

Bromocriptine because the risk of its side effects may be increased by Guaifenesin/Pseudoephedrine Controlled-Release Capsules

Guanethidine, guanadrel, mecamylamine, methyldopa, or reserpine because their effectiveness may be decreased by Guaifenesin/Pseudoephedrine Controlled-Release Capsules

This may not be a complete list of all interactions that may occur. Ask your health care provider if Guaifenesin/Pseudoephedrine Controlled-Release Capsules may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Guaifenesin/Pseudoephedrine Controlled-Release Capsules:

Use Guaifenesin/Pseudoephedrine Controlled-Release Capsules as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Take Guaifenesin/Pseudoephedrine Controlled-Release Capsules by mouth with or without food.

Take Guaifenesin/Pseudoephedrine Controlled-Release Capsules with a full glass of water (8 oz/240 mL) unless your doctor tells you otherwise.

If you miss a dose of Guaifenesin/Pseudoephedrine Controlled-Release Capsules, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Guaifenesin/Pseudoephedrine Controlled-Release Capsules.

Important safety information:

Guaifenesin/Pseudoephedrine Controlled-Release Capsules may cause dizziness. These effects may be worse if you take it with alcohol or certain medicines. Use Guaifenesin/Pseudoephedrine Controlled-Release Capsules with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

Do not take appetite suppressants while you are taking Guaifenesin/Pseudoephedrine Controlled-Release Capsules without checking with your doctor.

Guaifenesin/Pseudoephedrine Controlled-Release Capsules has pseudoephedrine in it. Before you start any new medicine, check the label to see if it has pseudoephedrine in it too. If it does or if you are not sure, check with your doctor or pharmacist.

Do NOT take more than the recommended dose or use for longer than prescribed without checking with your doctor.

If your symptoms do not get better within 5 to 7 days or if they get worse, check with your doctor.

Guaifenesin/Pseudoephedrine Controlled-Release Capsules may interfere with certain lab test results. Make sure that all of your doctors and lab personnel know that you are taking Guaifenesin/Pseudoephedrine Controlled-Release Capsules.

Tell your doctor or dentist that you take Guaifenesin/Pseudoephedrine Controlled-Release Capsules before you receive any medical or dental care, emergency care, or surgery.

Use Guaifenesin/Pseudoephedrine Controlled-Release Capsules with caution in the ELDERLY; they may be more sensitive to its effects.

Caution is advised when using Guaifenesin/Pseudoephedrine Controlled-Release Capsules in CHILDREN; they may be more sensitive to its effects.

PREGNANCY and BREAST-FEEDING: If you become pregnant while taking Guaifenesin/Pseudoephedrine Controlled-Release Capsules, contact your doctor. You will need to discuss the benefits and risks of using Guaifenesin/Pseudoephedrine Controlled-Release Capsules while pregnant. It is not known if Guaifenesin/Pseudoephedrine Controlled-Release Capsules are found in breast milk. Do not breast-feed while taking Guaifenesin/Pseudoephedrine Controlled-Release Capsules.

Possible side effects of Guaifenesin/Pseudoephedrine Controlled-Release Capsules:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Dizziness; excitability; headache; nausea; nervousness or anxiety; trouble sleeping; weakness.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); difficulty urinating; fast or irregular heartbeat; hallucinations; seizures; severe dizziness, lightheadedness, or headache; tremor.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Guaifenesin/Pseudoephedrine side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision; confusion; hallucinations; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; unusually fast, slow, or irregular heartbeat; vomiting.

Proper storage of Guaifenesin/Pseudoephedrine Controlled-Release Capsules:

Store Guaifenesin/Pseudoephedrine Controlled-Release Capsules at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Guaifenesin/Pseudoephedrine Controlled-Release Capsules out of the reach of children and away from pets.

General information:

If you have any questions about Guaifenesin/Pseudoephedrine Controlled-Release Capsules, please talk with your doctor, pharmacist, or other health care provider.

Guaifenesin/Pseudoephedrine Controlled-Release Capsules are to be used only by the patient for whom it is prescribed. Do not share it with other people.

If your symptoms do not improve or if they become worse, check with your doctor.

Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Guaifenesin/Pseudoephedrine Controlled-Release Capsules. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

More Guaifenesin/Pseudoephedrine resources

Guaifenesin/Pseudoephedrine Side Effects (in more detail)
Guaifenesin/Pseudoephedrine Use in Pregnancy & Breastfeeding
Drug Images
Guaifenesin/Pseudoephedrine Drug Interactions
Guaifenesin/Pseudoephedrine Support Group
58 Reviews for Guaifenesin/Pseudoephedrine - Add your own review/rating

Compare Guaifenesin/Pseudoephedrine with other medications

Cough and Nasal Congestion

Glynase

glyburide

Dosage Form: tablet
Glynase® PresTab®

micronized glyburide tablets

1.5, 3, and 6 mg

For Oral Use

Glynase Description

Glynase PresTab Tablets contain micronized (smaller particle size) glyburide, which is an oral blood-glucose-lowering drug of the sulfonylurea class. Glyburide is a white, crystalline compound, formulated as Glynase PresTab Tablets of 1.5, 3, and 6 mg strengths for oral administration. Inactive ingredients: colloidal silicon dioxide, corn starch, lactose, magnesium stearate. In addition, the 3 mg strength contains FD&C Blue No. 1 Aluminum Lake, and the 6 mg tablet contains D&C Yellow No. 10 Aluminum Lake. The chemical name for glyburide is 1-[[p-[2-(5-chloro-o-anisamido)ethyl]phenyl]-sulfonyl]-3-cyclohexylurea and the molecular weight is 493.99. The structural formula is represented below:

Glynase - Clinical Pharmacology

Actions

Glyburide appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The mechanism by which glyburide lowers blood glucose during long-term administration has not been clearly established. With chronic administration in Type II diabetic patients, the blood glucose lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may be involved in the mechanism of action of oral sulfonylurea hypoglycemic drugs. The combination of glyburide and metformin may have a synergistic effect, since both agents act to improve glucose tolerance by different but complementary mechanisms.

Some patients who are initially responsive to oral hypoglycemic drugs, including glyburide, may become unresponsive or poorly responsive over time. Alternatively, glyburide may be effective in some patients who have become unresponsive to one or more other sulfonylurea drugs.

In addition to its blood glucose lowering actions, glyburide produces a mild diuresis by enhancement of renal free water clearance. Disulfiram-like reactions have very rarely been reported in patients treated with glyburide.

Pharmacokinetics

Single dose studies with Glynase PresTab Tablets in normal subjects demonstrate significant absorption of glyburide within one hour, peak drug levels at about two to three hours, and low but detectable levels at twenty-four hours.

Bioavailability studies have demonstrated that Glynase PresTab Tablets 3 mg provide serum glyburide concentrations that are not bioequivalent to those from MICRONASE® Tablets 5 mg. Therefore, the patient should be retitrated.

In a single-dose bioavailability study (see Figure A) in which subjects received Glynase PresTab Tablets 3 mg and MICRONASE Tablets 5 mg with breakfast, the peak of the mean serum glyburide concentration-time curve was 97.2 ng/mL for Glynase PresTab Tablets 3 mg and 87.5 ng/mL for MICRONASE Tablets 5 mg. The mean of the individual maximum serum concentration values of glyburide (Cmax) from Glynase PresTab Tablets 3 mg was 106 ng/mL and that from MICRONASE Tablets 5 mg was 104 ng/mL. The mean glyburide area under the serum concentration-time curve (AUC) for this study was 568 ng × hr/mL for Glynase PresTab Tablets 3 mg and 746 ng × hr/mL for MICRONASE Tablets 5 mg.

Mean serum levels of glyburide, as reflected by areas under the serum concentration-time curve, increase in proportion to corresponding increases in dose. Multiple dose studies with glyburide in diabetic patients demonstrate drug level concentration-time curves similar to single dose studies, indicating no buildup of drug in tissue depots.

In a steady-state study in diabetic patients receiving Glynase PresTab Tablets 6 mg once daily or Glynase PresTab Tablets 3 mg twice daily, no difference was seen between the two dosage regimens in average 24-hour glyburide concentrations following two weeks of dosing. The once-daily and twice-daily regimens provided equivalent glucose control as measured by fasting plasma glucose levels, 4-hour postprandial glucose AUC values, and 24-hour glucose AUC values. Insulin AUC response over the 24-hour period was not different for the two regimens. There were differences in insulin response between the regimens for the breakfast and supper 4-hour postprandial periods, but these did not translate into differences in glucose control.

The serum concentration of glyburide in normal subjects decreased with a half-life of about four hours.

In single dose studies in fasting normal subjects who were administered glyburide (MICRONASE Tablets) in doses ranging from 1.25 mg to 5 mg, the degree and duration of blood glucose lowering is proportional to the dose administered and to the area under the drug level concentration-time curve. The blood glucose lowering effect persists for 24 hours following single morning doses in nonfasting diabetic patients. Under conditions of repeated administration in diabetic patients, however, there is no reliable correlation between blood drug levels and fasting blood glucose levels. A one year study of diabetic patients treated with glyburide showed no reliable correlation between administered dose and serum drug level.

The major metabolite of glyburide is the 4-trans-hydroxy derivative. A second metabolite, the 3-cis-hydroxy derivative, also occurs. These metabolites probably contribute no significant hypoglycemic action in humans since they are only weakly active (1/400th and 1/40th as active, respectively, as glyburide) in rabbits.

Glyburide is excreted as metabolites in the bile and urine, approximately 50% by each route. This dual excretory pathway is qualitatively different from that of other sulfonylureas, which are excreted primarily in the urine.

Sulfonylurea drugs are extensively bound to serum proteins. Displacement from protein binding sites by other drugs may lead to enhanced hypoglycemic action. In vitro, the protein binding exhibited by glyburide is predominantly non-ionic, whereas that of other sulfonylureas (chlorpropamide, tolbutamide, tolazamide) is predominantly ionic. Acidic drugs such as phenylbutazone, warfarin, and salicylates displace the ionic-binding sulfonylureas from serum proteins to a far greater extent than the non-ionic binding glyburide. It has not been shown that this difference in protein binding will result in fewer drug-drug interactions with glyburide in clinical use.

Indications and Usage for Glynase

Glynase PresTab Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Contraindications

Glynase PresTab Tablets are contraindicated in patients with:

Known hypersensitivity or allergy to the drug.

Diabetic ketoacidosis, with or without coma. This condition should be treated with insulin.

Type I diabetes mellitus.

SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY

The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups (Diabetes, 19 (Suppl. 2):747–830, 1970).

UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2 1/2 times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of Glynase PresTab and of alternative modes of therapy.

Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.

Precautions

Macrovascular Outcomes

There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with Glynase PresTab or any other anti-diabetic drug.

Bioavailability studies have demonstrated that Glynase PresTab Tablets 3 mg provide serum glyburide concentrations that are not bioequivalent to those from MICRONASE Tablets 5 mg. Therefore, patients should be retitrated when transferred from MICRONASE or Diabeta® or other oral hypoglycemic agents.

General

Hypoglycemia

All sulfonylureas are capable of producing severe hypoglycemia. Proper patient selection and dosage and instructions are important to avoid hypoglycemic episodes. Renal or hepatic insufficiency may cause elevated drug levels of glyburide and the latter may also diminish gluconeogenic capacity, both of which increase the risk of serious hypoglycemic reactions. Elderly, debilitated or malnourished patients, and those with adrenal or pituitary insufficiency, are particularly susceptible to the hypoglycemic action of glucose-lowering drugs. Hypoglycemia may be difficult to recognize in the elderly and in people who are taking beta-adrenergic blocking drugs. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when alcohol is ingested, or when more than one glucose lowering drug is used. The risk of hypoglycemia may be increased with combination therapy.

Loss of Control of Blood Glucose

When a patient stabilized on any diabetic regimen is exposed to stress such as fever, trauma, infection or surgery, a loss of control may occur. At such times it may be necessary to discontinue Glynase PresTab and administer insulin.

The effectiveness of any hypoglycemic drug, including Glynase PresTab, in lowering blood glucose to a desired level decreases in many patients over a period of time which may be due to progression of the severity of diabetes or to diminished responsiveness to the drug. This phenomenon is known as secondary failure, to distinguish it from primary failure in which the drug is ineffective in an individual patient when Glynase PresTab is first given. Adequate adjustment of dose and adherence to diet should be assessed before classifying a patient as a secondary failure.

Hemolytic Anemia

Treatment of patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency with sulfonylurea agents can lead to hemolytic anemia. Because Glynase PresTab belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD deficiency and a non-sulfonylurea alternative should be considered. In post marketing reports, hemolytic anemia has also been reported in patients who did not have known G6PD deficiency.

Information for Patients

Patients should be informed of the potential risks and advantages of Glynase PresTab and of alternative modes of therapy. They also should be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of urine and/or blood glucose.

The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members. Primary and secondary failure also should be explained.

Physician Counseling Information for Patients

In initiating treatment for type 2 diabetes, diet should be emphasized as the primary form of treatment. Caloric restriction and weight loss are essential in the obese diabetic patient. Proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycemia. The importance of regular physical activity should also be stressed, and cardiovascular risk factors should be identified and corrective measures taken where possible. Use of Glynase PresTab or other antidiabetic medications must be viewed by both the physician and patient as a treatment in addition to diet and not as a substitution or as a convenient mechanism for avoiding dietary restraint. Furthermore, loss of blood glucose control on diet alone may be transient, thus requiring only short-term administration of Glynase PresTab or other antidiabetic medications. Maintenance or discontinuation of Glynase PresTabs or other antidiabetic medications should be based on clinical judgment using regular clinical and laboratory evaluations.

Laboratory Tests

Therapeutic response to Glynase PresTab Tablets should be monitored by frequent urine glucose tests and periodic blood glucose tests. Measurement of glycosylated hemoglobin levels may be helpful in some patients.

Drug Interactions

The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving glyburide, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving glyburide, the patient should be observed closely for loss of control.

Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving glyburide, the patient should be closely observed for loss of control. When such drugs are withdrawn from a patient receiving glyburide, the patient should be observed closely for hypoglycemia.

A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide. The mechanism of action for this interaction is not known.

A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical or vaginal preparations of miconazole is not known.

Metformin

In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain. Coadministration of glyburide and metformin did not result in any changes in either metformin pharmacokinetics or pharmacodynamics.

Carcinogenesis, Mutagenesis, and Impairment of Fertility

Studies in rats at doses up to 300 mg/kg/day for 18 months showed no carcinogenic effects. Glyburide is nonmutagenic when studied in the Salmonella microsome test (Ames test) and in the DNA damage/alkaline elution assay.

No drug-related effects were noted in any of the criteria evaluated in the two-year oncogenicity study of glyburide in mice.

Pregnancy

Teratogenic Effects

Pregnancy Category B

Reproduction studies have been performed in rats and rabbits at doses up to 500 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to glyburide. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Because recent information suggests that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities, many experts recommend that insulin be used during pregnancy to maintain blood glucose as close to normal as possible.

Nonteratogenic Effects

Prolonged severe hypoglycemia (4 to 10 days) has been reported in neonates born to mothers who were receiving a sulfonylurea drug at the time of delivery. This has been reported more frequently with the use of agents with prolonged half-lives. If Glynase PresTab is used during pregnancy, it should be discontinued at least two weeks before the expected delivery date.

Nursing Mothers

Although it is not known whether glyburide is excreted in human milk, some sulfonylurea drugs are known to be excreted in human milk. Because the potential for hypoglycemia in nursing infants may exist, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. If the drug is discontinued, and if diet alone is inadequate for controlling blood glucose, insulin therapy should be considered.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

Geriatric Use

Elderly patients are particularly susceptible to the hypoglycemic action of glucose lowering drugs. Hypoglycemia may be difficult to recognize in the elderly (see PRECAUTIONS). The initial and maintenance dosing should be conservative to avoid hypoglycemic reactions (see DOSAGE AND ADMINISTRATION).

Elderly patients are prone to develop renal insufficiency, which may put them at risk of hypoglycemia. Dose selection should include assessment of renal function.

Adverse Reactions

Hypoglycemia: See PRECAUTIONS and OVERDOSAGE Sections.

Gastrointestinal Reactions: Cholestatic jaundice and hepatitis may occur rarely which may progress to liver failure; Glynase PresTab Tablets should be discontinued if this occurs.

Liver function abnormalities, including isolated transaminase elevations, have been reported.

Gastrointestinal disturbances, eg, nausea, epigastric fullness, and heartburn are the most common reactions, having occurred in 1.8% of treated patients during clinical trials. They tend to be dose related and may disappear when dosage is reduced.

Dermatologic Reactions: Allergic skin reactions, eg, pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions occurred in 1.5% of treated patients during clinical trials. These may be transient and may disappear despite continued use of glyburide. If skin reactions persist, the drug should be discontinued.

Porphyria cutanea tarda and photosensitivity reactions have been reported with sulfonylureas.

Hematologic Reactions: Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia (see PRECAUTIONS), aplastic anemia, and pancytopenia have been reported with sulfonylureas.

Metabolic Reactions: Hepatic porphyria and disulfiram-like reactions have been reported with sulfonylureas; however, hepatic porphyria has not been reported with glyburide and disulfiram-like reactions have been reported very rarely.

Cases of hyponatremia have been reported with glyburide and all other sulfonylureas, most often in patients who are on other medications or have medical conditions known to cause hyponatremia or increase release of antidiuretic hormone. The syndrome of inappropriate antidiuretic hormone (SIADH) secretion has been reported with certain other sulfonylureas, and it has been suggested that these sulfonylureas may augment the peripheral (antidiuretic) action of ADH and/or increase release of ADH.

Other Reactions: Changes in accommodation and/or blurred vision have been reported with glyburide and other sulfonylureas. These are thought to be related to fluctuation in glucose levels.

In addition to dermatologic reactions, allergic reactions such as angioedema, arthralgia, myalgia and vasculitis have been reported.

Overdosage

Overdosage of sulfonylureas, including glyburide, can produce hypoglycemia. Mild hypoglycemic symptoms, without loss of consciousness or neurological findings, should be treated aggressively with oral glucose and adjustments in drug dosage and/or meal patterns. Close monitoring should continue until the physician is assured that the patient is out of danger. Severe hypoglycemic reactions with coma, seizure, or other neurological impairment occur infrequently, but constitute medical emergencies requiring immediate hospitalization. If hypoglycemic coma is diagnosed or suspected, the patient should be given a rapid intravenous injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of a more dilute (10%) glucose solution at a rate which will maintain the blood glucose at a level above 100 mg/dL. Patients should be closely monitored for a minimum of 24 to 48 hours, since hypoglycemia may recur after apparent clinical recovery.

Glynase Dosage and Administration

Patients should be retitrated when transferred from MICRONASE or Diabeta or other oral hypoglycemic agents.

There is no fixed dosage regimen for the management of diabetes mellitus with Glynase PresTab Tablets or any other hypoglycemic agent. In addition to the usual monitoring of urinary glucose, the patient's blood glucose must also be monitored periodically to determine the minimum effective dose for the patient; to detect primary failure, ie, inadequate lowering of blood glucose at the maximum recommended dose of medication; and to detect secondary failure, ie, loss of adequate blood glucose lowering response after an initial period of effectiveness. Glycosylated hemoglobin levels may also be of value in monitoring the patient's response to therapy.

Short-term administration of Glynase PresTab may be sufficient during periods of transient loss of control in patients usually controlled well on diet.

Usual Starting Dose

The suggested starting dose of Glynase PresTab is 1.5 to 3 mg daily, administered with breakfast or the first main meal. Those patients who may be more sensitive to hypoglycemic drugs should be started at 0.75 mg daily. (See PRECAUTIONS Section for patients at increased risk.) Failure to follow an appropriate dosage regimen may precipitate hypoglycemia. Patients who do not adhere to their prescribed dietary and drug regimen are more prone to exhibit unsatisfactory response to therapy.

Transfer From Other Hypoglycemic Therapy; Patients Receiving Other Oral Antidiabetic Therapy

Patients should be retitrated when transferred from MICRONASE or other oral hypoglycemic agents. The initial daily dose should be 1.5 to 3 mg. When transferring patients from oral hypoglycemic agents other than chlorpropamide to Glynase PresTab, no transition period and no initial or priming dose are necessary. When transferring patients from chlorpropamide, particular care should be exercised during the first two weeks because the prolonged retention of chlorpropamide in the body and subsequent overlapping drug effects may provoke hypoglycemia.

Patients Receiving Insulin

Some Type II diabetic patients being treated with insulin may respond satisfactorily to Glynase PresTab. If the insulin dose is less than 20 units daily, substitution of Glynase PresTab 1.5 to 3 mg as a single daily dose may be tried. If the insulin dose is between 20 and 40 units daily, the patient may be placed directly on Glynase PresTab Tablets 3 mg daily as a single dose. If the insulin dose is more than 40 units daily, a transition period is required for conversion to Glynase PresTab. In these patients, insulin dosage is decreased by 50% and Glynase PresTab Tablets 3 mg daily is started. Please refer to Titration to Maintenance Dose for further explanation.

Titration to Maintenance Dose

The usual maintenance dose is in the range of 0.75 to 12 mg daily, which may be given as a single dose or in divided doses (See Dosage Interval Section). Dosage increases should be made in increments of no more than 1.5 mg at weekly intervals based upon the patient's blood glucose response.

No exact dosage relationship exists between Glynase PresTab and the other oral hypoglycemic agents, including MICRONASE or Diabeta. Although patients may be transferred from the maximum dose of other sulfonylureas, the maximum starting dose of 3 mg of Glynase PresTab Tablets should be observed. A maintenance dose of 3 mg of Glynase PresTab Tablets provides approximately the same degree of blood glucose control as 250 to 375 mg chlorpropamide, 250 to 375 mg tolazamide, 5 mg of glyburide (nonmicronized tablets), 500 to 750 mg acetohexamide, or 1000 to 1500 mg tolbutamide.

When transferring patients receiving more than 40 units of insulin daily, they may be started on a daily dose of Glynase PresTab Tablets 3 mg concomitantly with a 50% reduction in insulin dose. Progressive withdrawal of insulin and increase of Glynase PresTab in increments of 0.75 to 1.5 mg every 2 to 10 days is then carried out. During this conversion period when both insulin and Glynase PresTab are being used, hypoglycemia may rarely occur. During insulin withdrawal, patients should test their urine for glucose and acetone at least three times daily and report results to their physician. The appearance of persistent acetonuria with glycosuria indicates that the patient is a Type I diabetic who requires insulin therapy.

Concomitant Glyburide and Metformin Therapy

Glynase PresTab Tablets should be added gradually to the dosing regimen of patients who have not responded to the maximum dose of metformin monotherapy after four weeks (see Usual Starting Dose and Titration to Maintenance Dose). Refer to metformin package insert.

With concomitant glyburide and metformin therapy, the desired control of blood glucose may be obtained by adjusting the dose of each drug. However, attempts should be made to identify the optimal dose of each drug needed to achieve this goal. With concomitant glyburide and metformin therapy, the risk of hypoglycemia associated with sulfonylurea therapy continues and may be increased. Appropriate precautions should be taken (see PRECAUTIONS Section).

Maximum Dose

Daily doses of more than 12 mg are not recommended.

Dosage Interval

Once-a-day therapy is usually satisfactory. Some patients, particularly those receiving more than 6 mg daily, may have a more satisfactory response with twice-a-day dosage.

Specific Patient Populations

Glynase PresTab Tablets are not recommended for use in pregnancy or for use in pediatric patients.

In elderly patients, debilitated or malnourished patients, and patients with impaired renal or hepatic function, the initial and maintenance dosing should be conservative to avoid hypoglycemic reactions. (See PRECAUTIONS Section.)

How is Glynase Supplied

Glynase PresTab Tablets are supplied as follows:

Glynase PresTab Tablets 1.5 mg

(white, ovoid, imprinted Glynase 1.5/PT Score PT, contour, scored)

Plastic Bottles of 100	NDC 0009-0341-01
Unit Dose Package of 100	NDC 0009-0341-02

Glynase PresTab Tablets 3 mg

(blue, ovoid, imprinted Glynase 3/PT Score PT, contour, scored)

Plastic Bottles of 100	NDC 0009-0352-01
Plastic Bottles of 500	NDC 0009-0352-03
Plastic Bottles of 1000	NDC 0009-0352-04
Unit Dose Package of 100	NDC 0009-0352-02

Glynase PresTab Tablets 6 mg

(yellow, ovoid, imprinted Glynase 6/PT Score PT, contour, scored)

Plastic Bottles of 100	NDC 0009-3449-01
Plastic Bottles of 500	NDC 0009-3449-03

The PresTab Tablet can be easily divided in half for a more flexible dosing regimen. Press gently on the score and the PresTab Tablet will split in even halves.

Rx only

Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP]. Dispensed in well closed containers with safety closures. Keep container tightly closed.

Diabeta is a trademark of Hoechst-Roussel Pharmaceuticals, Inc.

LAB-0110-5.0

May 2010

PRINCIPAL DISPLAY PANEL - 1.5 mg - 100 Tablet Bottle

NDC 0009-0341-01

100 Tablets

Rx only

Glynase® PresTab®

micronized glyburide

tablets

1.5 mg

Pfizer

Distributed by

Pharmacia & Upjohn Co

Division of Pfizer Inc, NY, NY 10017

PRINCIPAL DISPLAY PANEL - 3 mg - 1000 Tablet Bottle

NDC 0009-0352-04

1000 Tablets

Rx only

Glynase® PresTab®

micronized glyburide

tablets

3 mg

Pfizer

Distributed by

Pharmacia & Upjohn Co

Division of Pfizer Inc, NY, NY 10017

PRINCIPAL DISPLAY PANEL - 6 mg - 500 Tablet Bottle

NDC 0009-3449-03

500 Tablets

Rx only

Glynase® PresTab®

micronized glyburide

tablets

6 mg

Pfizer

Distributed by

Pharmacia & Upjohn Co

Division of Pfizer Inc, NY, NY 10017

Glynase
glyburide tablet

Product Information
Product Type	HUMAN PRESCRIPTION DRUG	NDC Product Code (Source)	0009-0341
Route of Administration	ORAL	DEA Schedule

Active Ingredient/Active Moiety
Ingredient Name	Basis of Strength	Strength
glyburide (glyburide)	glyburide	1.5 mg

Inactive Ingredients
Ingredient Name	Strength
silicon dioxide
starch, corn
lactose
magnesium stearate

Product Characteristics
Color	WHITE	Score	2 pieces
Shape	OVAL (ovoid contoured)	Size	11mm
Flavor		Imprint Code	Glynase;1;5;PT
Contains

Packaging
#	NDC	Package Description	Multilevel Packaging
1	0009-0341-01	100 TABLET In 1 BOTTLE, PLASTIC	None
2	0009-0341-02	100 TABLET In 1 BLISTER PACK	None

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA020051	03/04/1992

Glynase
glyburide tablet

Product Information
Product Type	HUMAN PRESCRIPTION DRUG	NDC Product Code (Source)	0009-0352
Route of Administration	ORAL	DEA Schedule

Active Ingredient/Active Moiety
Ingredient Name	Basis of Strength	Strength
glyburide (glyburide)	glyburide	3 mg

Inactive Ingredients
Ingredient Name	Strength
silicon dioxide
starch, corn
lactose
magnesium stearate
FD&C Blue No. 1
Aluminum Oxide

Product Characteristics
Color	BLUE	Score	2 pieces
Shape	OVAL (ovoid contoured)	Size	11mm
Flavor		Imprint Code	Glynase;3;PT
Contains

Packaging
#	NDC	Package Description	Multilevel Packaging
1	0009-0352-01	100 TABLET In 1 BOTTLE, PLASTIC	None
2	0009-0352-03	500 TABLET In 1 BOTTLE, PLASTIC	None
3	0009-0352-04	1000 TABLET In 1 BOTTLE, PLASTIC	None
4	0009-0352-02	100 TABLET In 1 BLISTER PACK	None

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA020051	03/04/1992

Glynase
glyburide tablet

Product Information
Product Type	HUMAN PRESCRIPTION DRUG	NDC Product Code (Source)	0009-3449
Route of Administration	ORAL	DEA Schedule

Active Ingredient/Active Moiety
Ingredient Name	Basis of Strength	Strength
glyburide (glyburide)	glyburide	6 mg

Inactive Ingredients
Ingredient Name	Strength
silicon dioxide
starch, corn
lactose
magnesium stearate
D&C Yellow No. 10
Aluminum Oxide

Product Characteristics
Color	YELLOW	Score	2 pieces
Shape	OVAL (ovoid contoured)	Size	11mm
Flavor		Imprint Code	Glynase;6;PT
Contains

Packaging
#	NDC	Package Description	Multilevel Packaging
1	0009-3449-01	100 TABLET In 1 BOTTLE, PLASTIC	None
2	0009-3449-03	500 TABLET In 1 BOTTLE, PLASTIC	None

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA020051	03/04/1992

Labeler - Pharmacia and Upjohn Company (829076566)

Establishment
Name	Address	ID/FEI	Operations
Pharmacia and Upjohn Company		829076566	API MANUFACTURE, MANUFACTURE

Establishment
Name	Address	ID/FEI	Operations
Pfizer Pharmaceuticals LLC		193684656	MANUFACTURE

Establishment
Name	Address	ID/FEI	Operations
Warner Lambert Company LLC		001344506	ANALYSIS

Revised: 02/2011Pharmacia and Upjohn Company

More Glynase resources

Glynase Side Effects (in more detail)
Glynase Dosage
Glynase Use in Pregnancy & Breastfeeding
Glynase Drug Interactions
Glynase Support Group
0 Reviews for Glynase - Add your own review/rating

Compare Glynase with other medications

Diabetes, Type 2

Imuran

In some countries, this medicine may only be approved for veterinary use.

In the US, Imuran (azathioprine systemic) is a member of the following drug classes: antirheumatics, other immunosuppressants and is used to treat Atopic Dermatitis, Biliary Cirrhosis, Bullous Pemphigoid, Chronic Active Hepatitis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Cogan's Syndrome, Crohn's Disease - Acute, Crohn's Disease - Maintenance, Dermatomyositis, Eczema, Glomerulonephritis, Idiopathic Thrombocytopenic Purpura, Multiple Sclerosis, Myasthenia Gravis, Myopathy, Nephrotic Syndrome, Neurosarcoidosis, Organ Transplant - Rejection Prophylaxis, Pemphigoid, Pemphigus, Renal Transplant, Rheumatoid Arthritis, Sarcoidosis, Systemic Lupus Erythematosus, Takayasu's Arteritis, Ulcerative Colitis and Uveitis.

US matches:

Imuran

UK matches:

Imuran Injection (SPC)

Ingredient matches for Imuran

Azathioprine

Azathioprine is reported as an ingredient of Imuran in the following countries:

Argentina

Australia

Bahrain

Bangladesh

Belgium

Bosnia & Herzegowina

Brazil

Bulgaria

Canada

Chile

China

Croatia (Hrvatska)

Czech Republic

Ecuador

Estonia

Ethiopia

Georgia

Guyana

Hong Kong

Hungary

India

Indonesia

Iran

Ireland

Israel

Japan

Kuwait

Latvia

Lithuania

Luxembourg

Malaysia

Mexico

Netherlands

New Zealand

Oman

Philippines

Poland

Portugal

Qatar

Romania

Serbia

Singapore

Slovenia

South Africa

Taiwan

Thailand

Turkey

United Arab Emirates

United Kingdom

United States

Azathioprine sodium salt (a derivative of Azathioprine) is reported as an ingredient of Imuran in the following countries:

Canada

Ireland

Netherlands

New Zealand

United States

International Drug Name Search

Glossary

SPC

Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Gumsol

Generic Name: benzocaine (Oral route, Oromucosal route)

BEN-zoe-kane

Commonly used brand name(s)

In the U.S.

Anbesol

Babee Teething

Benzodent

Benz-O-Sthetic

Bi-Zets/Benzo-Troches

Dentemp's

Dent-O-Kain/20

Detane

Gumsol

Hurricaine

Hurricane Spray Kit

Kank-A Soft Brush

Larynex

Miradyne-3

Mycinette

Orabase-B

Oracaine

Ora film

Orajel

OraMagic Plus

Orasol

Red Cross Canker Sore

Thorets

Trocaine

Zetts

Zilactin

Zilactin-B

In Canada

Anbesol Extra Strength

Anbesol Liquid

Baby Anbesol

Baby Orajel

Baby Orajel Liquid

Maximum Strength Orajel Pm

Orajel Extra Strength

Available Dosage Forms:

Liquid

Gel/Jelly

Solution

Lozenge/Troche

Film

Lotion

Ointment

Powder for Suspension

Cream

Tablet, Disintegrating

Swab

Spray

Paste

Therapeutic Class: Anesthetic, Local

Chemical Class: Amino Ester

Uses For Gumsol

Benzocaine lozenges are used to relieve pain and irritation caused by sore throat, sore mouth, or canker sores.

This medicine is available without a prescription; however, your doctor may have special instructions on the proper use and dose for your medical problem.

Before Using Gumsol

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

No information is available on the relationship of age to the effects of benzocaine lozenges in the pediatric population. Safety and efficacy have not been established in children below 5 years of age.

Geriatric

No information is available on the relationship of age to the effects of benzocaine in geriatric patients.

Interactions with Medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.

Interactions with Food/Tobacco/Alcohol

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.

Proper Use of benzocaine

This section provides information on the proper use of a number of products that contain benzocaine. It may not be specific to Gumsol. Please read with care.

Use this medicine exactly as directed by your doctor. Do not use more of this medicine, do not use it more often, and do not use it for a longer time than directed. To do so may increase the chance of absorption into the body and the risk of side effects.

This medicine should be used only for problems being treated by your doctor or conditions listed in the package directions. Check with your doctor before using it for other problems, especially if you think that an infection may be present.

Do not use this medicine for more than 2 days without checking first with your doctor.

Dosing

The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

For oral dosage form (lozenges):
- For sore throat and mouth pain:
  - Adults, teenagers, and children 5 years of age and older—One lozenge, dissolved slowly in the mouth every 2 hours as needed.
  - Children younger than 5 years of age—Use is not recommended.

Missed Dose

If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.

Storage

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.

Keep out of the reach of children.

Do not keep outdated medicine or medicine no longer needed.

Ask your healthcare professional how you should dispose of any medicine you do not use.

Precautions While Using Gumsol

If your condition does not improve within 7 days, or if it becomes worse, check with your doctor.

Call your doctor right away if you start to have a severe sore throat or sore throat that occurs with a high fever, headache, nausea, or vomiting. These maybe signs of an infection.

Gumsol Side Effects

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur:

Incidence not known

Headache

high fever

nausea

vomiting

worsening of pain, redness, swelling, or irritation in or around the mouth

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.

The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.

More Gumsol resources

Gumsol Use in Pregnancy & Breastfeeding
Gumsol Support Group
6 Reviews for Gumsol - Add your own review/rating

Compare Gumsol with other medications

Anal Itching
Anesthesia
Aphthous Ulcer
Burns, External
Cold Sores
Hemorrhoids
Oral and Dental Conditions
Pain
Pruritus
Sunburn
Tonsillitis/Pharyngitis

Thursday, September 29, 2016

Gly-Cort

Generic Name: hydrocortisone (Topical application route)

hye-droe-KOR-ti-sone

Commonly used brand name(s)

In the U.S.

Ala-Cort

Ala-Scalp HP

Anusol HC

Aquanil HC

Beta HC

Caldecort

Cetacort

Corta-Cap

Cortagel Extra Strength

Cortaid

CortAlo With Aloe

Corticaine

Corticool Maximum Strength

Cortizone-10

Cortizone-5

Cotacort

Delacort

Dermarest

Dermtex-HC

Foille Cort

Gly-Cort

Hydrozone Plus

Hytone

Instacort-10

Ivy Soothe

IvyStat

Keratol HC

Kericort 10

Lacticare-HC

Locoid

Locoid Lipocream

Medi-Cortisone Maximum Strength

Microcort

Mycin Scalp

Neutrogena T/Scalp

NuCort

Nupercainal HC

Nutracort

Pandel

Pediaderm HC Kit

Preparation H Hydrocortisone

Proctocream-HC

Recort Plus

Sarnol-HC Maximum Strength

Scalacort

Scalpcort

Summer's Eve Specialcare

Texacort

Therasoft Anti-Itch & Dermatitis

U-Cort

Westcort

In Canada

Barriere-Hc

Cortate

Cort-Eze

Cortoderm Mild Ointment

Cortoderm Regular Ointment

Emo-Cort

Emo-Cort Scalp Solution

Hydrocortisone Cream

Novo-Hydrocort

Novo-Hydrocort Cream

Prevex Hc

Sarna Hc

Available Dosage Forms:

Solution

Cream

Spray

Lotion

Ointment

Liquid

Gel/Jelly

Foam

Stick

Paste

Therapeutic Class: Corticosteroid, Weak

Pharmacologic Class: Adrenal Glucocorticoid

Uses For Gly-Cort

Hydrocortisone topical is used to help relieve redness, itching, swelling, or other discomfort caused by skin conditions. This medicine is a corticosteroid (cortisone-like medicine or steroid).

This medicine is available both over-the-counter (OTC) and with your doctor's prescription.

Before Using Gly-Cort

Allergies

Pediatric

Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of hydrocortisone topical in the pediatric population. However, because of this medicine's toxicity, it should be used with caution. Children may absorb large amounts through the skin, which can cause serious side effects. If your child is using this medicine, follow your doctor's instructions very carefully.

Geriatric

No information is available on the relationship of age to the effects of hydrocortisone topical in geriatric patients.

Interactions with Medicines

Interactions with Food/Tobacco/Alcohol

Proper Use of hydrocortisone

This section provides information on the proper use of a number of products that contain hydrocortisone. It may not be specific to Gly-Cort. Please read with care.

It is very important that you use this medicine only as directed by your doctor. Do not use more of it, do not use it more often, and do not use it for a longer time than your doctor ordered. To do so may cause unwanted side effects or skin irritation.

This medicine is for use on the skin only. Do not get it in your eyes. Do not use it on skin areas that have cuts, scrapes, or burns. If it does get on these areas, rinse it off right away with water.

This medicine should only be used for skin conditions that your doctor is treating. Check with your doctor before using it for other conditions, especially if you think that a skin infection may be present. This medicine should not be used to treat certain kinds of skin infections or conditions, such as severe burns.

To use:

Wash your hands with soap and water before and after using this medicine.

Apply a thin layer of this medicine to the affected area of the skin. Rub it in gently.

With the lotion, shake it well before using.

Do not bandage or otherwise wrap the skin being treated unless directed to do so by your doctor.

If the medicine is applied to the diaper area of an infant, do not use tight-fitting diapers or plastic pants unless directed to do so by your doctor.

If your doctor ordered an occlusive dressing or airtight covering to be applied over the medicine, make sure you know how to apply it. Occlusive dressings increase the amount of medicine absorbed through your skin, so use them only as directed. If you have any questions about this, check with your doctor.

Dosing

For redness, itching, and swelling of the skin:
- For topical dosage form (cream):
  - Adults—Apply to the affected area of the skin two or three times per day.
  - Children—Apply to the affected area of the skin two or three times per day.
- For topical dosage form (lotion):
  - Adults—Apply to the affected area of the skin two to four times per day.
  - Children—Apply to the affected area of the skin two to four times per day.
- For topical dosage form (ointment):
  - Adults—Apply to the affected area of the skin three or four times per day.
  - Children—Apply to the affected area of the skin three or four times per day.
- For topical dosage form (solution):
  - Adults—Apply to the affected area of the skin three or four times per day.
  - Children—Apply to the affected area of the skin three or four times per day.

Missed Dose

If you miss a dose of this medicine, apply it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.

Storage

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.

Keep out of the reach of children.

Do not keep outdated medicine or medicine no longer needed.

Ask your healthcare professional how you should dispose of any medicine you do not use.

Precautions While Using Gly-Cort

It is very important that your doctor check your or your child's progress at regular visits for any unwanted effects that may be caused by this medicine.

If your or your child's symptoms do not improve within a few days, or if they become worse, check with your doctor.

Using too much of this medicine or using it for a long time may increase your risk of having adrenal gland problems. The risk is greater for children and patients who use large amounts for a long time. Talk to your doctor right away if you or your child have more than one of these symptoms while you are using this medicine: blurred vision; dizziness or fainting; a fast, irregular, or pounding heartbeat; increased thirst or urination; irritability; or unusual tiredness or weakness.

Stop using this medicine and check with your doctor right away if you or your child have a skin rash, burning, stinging, swelling, or irritation on the skin.

Do not use cosmetics or other skin care products on the treated areas.

Gly-Cort Side Effects

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur:

Incidence not known

Blistering, burning, crusting, dryness, or flaking of the skin

irritation

itching, scaling, severe redness, soreness, or swelling of the skin

redness and scaling around the mouth

thinning of the skin with easy bruising, especially when used on the face or where the skin folds together (e.g. between the fingers)

thinning, weakness, or wasting away of the skin

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Incidence not known

Acne or pimples

burning and itching of the skin with pinhead-sized red blisters

burning, itching, and pain in hairy areas, or pus at the root of the hair

increased hair growth on the forehead, back, arms, and legs

lightening of normal skin color

lightening of treated areas of dark skin

reddish purple lines on the arms, face, legs, trunk, or groin

softening of the skin

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: Gly-Cort side effects (in more detail)

More Gly-Cort resources

Gly-Cort Side Effects (in more detail)
Gly-Cort Use in Pregnancy & Breastfeeding
Gly-Cort Drug Interactions
Gly-Cort Support Group
0 Reviews for Gly-Cort - Add your own review/rating

Gly-Cort Concise Consumer Information (Cerner Multum)

Anucort-HC cream, ointment, suppository Concise Consumer Information (Cerner Multum)

Anusol-HC Cream MedFacts Consumer Leaflet (Wolters Kluwer)

Carmol HC Prescribing Information (FDA)

Carmol HC Concise Consumer Information (Cerner Multum)

Carmol HC MedFacts Consumer Leaflet (Wolters Kluwer)

Cortizone-10 Cream MedFacts Consumer Leaflet (Wolters Kluwer)

Hydrocortisone Acetate Monograph (AHFS DI)

Hydrocortisone with Aloe Cream MedFacts Consumer Leaflet (Wolters Kluwer)

Hytone Prescribing Information (FDA)

Instacort Gel MedFacts Consumer Leaflet (Wolters Kluwer)

Locoid Cream MedFacts Consumer Leaflet (Wolters Kluwer)

Locoid Lipocream Prescribing Information (FDA)

Locoid Lotion Prescribing Information (FDA)

Nutracort Concise Consumer Information (Cerner Multum)

Nutracort Lotion MedFacts Consumer Leaflet (Wolters Kluwer)

Pandel Prescribing Information (FDA)

Pediaderm HC Lotion MedFacts Consumer Leaflet (Wolters Kluwer)

ProctoCream-HC Cream MedFacts Consumer Leaflet (Wolters Kluwer)

Proctocort Prescribing Information (FDA)

Texacort Prescribing Information (FDA)

U-cort Prescribing Information (FDA)

Westcort Prescribing Information (FDA)

Compare Gly-Cort with other medications

Anal Itching
Aphthous Stomatitis, Recurrent
Atopic Dermatitis
Dermatitis
Eczema
Gingivitis
Proctitis
Pruritus
Psoriasis
Seborrheic Dermatitis
Skin Rash

Esophageal Hemorrhage Medications

There are currently no drugs listed for "Esophageal Hemorrhage".

Learn more about Esophageal Hemorrhage

Medical Encyclopedia:

Bleeding esophageal varices

Drug List:

Mylepsin

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Mylepsin

Primidone

Primidone is reported as an ingredient of Mylepsin in the following countries:

United States

International Drug Name Search

Flunarizin-CT

Flunarizin-CT may be available in the countries listed below.

Ingredient matches for Flunarizin-CT

Flunarizine

Flunarizine dihydrochloride (a derivative of Flunarizine) is reported as an ingredient of Flunarizin-CT in the following countries:

Germany

International Drug Name Search

Adrenaline Hydrochloride Injection

Adrenaline Hydrochloride Injection may be available in the countries listed below.

Ingredient matches for Adrenaline Hydrochloride Injection

Epinephrine

Epinephrine hydrochloride (a derivative of Epinephrine) is reported as an ingredient of Adrenaline Hydrochloride Injection in the following countries:

Australia

International Drug Name Search

Genoptic

Generic Name: gentamicin (Ophthalmic route)

jen-ta-MYE-sin

Commonly used brand name(s)

In the U.S.

Garamycin

Genoptic

Genoptic S.O.P.

Gentacidin

Gentafair

Gentak

Gentasol

Ocu-Mycin

Available Dosage Forms:

Solution

Ointment

Therapeutic Class: Antibiotic

Chemical Class: Aminoglycoside

Uses For Genoptic

Gentamicin belongs to the family of medicines called antibiotics. Gentamicin ophthalmic preparations are used to treat infections of the eye.

Gentamicin is available only with your doctor's prescription.

Before Using Genoptic

Allergies

Pediatric

There is no specific information comparing use of this medicine in babies up to one month of age with use in other age groups.

Geriatric

Many medicines have not been studied specifically in older people. Therefore, it may not be known whether they work exactly the same way they do in younger adults or if they cause different side effects or problems in older people. There is no specific information comparing use of this medicine in the elderly with use in other age groups.

Pregnancy

	Pregnancy Category	Explanation
All Trimesters	D	Studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy in a life threatening situation or a serious disease, may outweigh the potential risk.

Breast Feeding

Studies in women suggest that this medication poses minimal risk to the infant when used during breastfeeding.

Interactions with Medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.

Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

Alcuronium

Atracurium

Cidofovir

Cisatracurium

Colistimethate Sodium

Decamethonium

Doxacurium

Ethacrynic Acid

Fazadinium

Furosemide

Gallamine

Hexafluorenium

Lysine

Metocurine

Mivacurium

Pancuronium

Pipecuronium

Rapacuronium

Rocuronium

Succinylcholine

Tacrolimus

Tubocurarine

Vancomycin

Vecuronium

Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

Indomethacin

Methoxyflurane

Polygeline

Interactions with Food/Tobacco/Alcohol

Proper Use of gentamicin

This section provides information on the proper use of a number of products that contain gentamicin. It may not be specific to Genoptic. Please read with care.

For patients using the eye drop form of this medicine:

The bottle is only partially full to provide proper drop control.

To use:
- First, wash your hands. Tilt the head back and with the index finger of one hand, press gently on the skin just beneath the lower eyelid and pull the lower eyelid away from the eye to make a space. Drop the medicine into this space. Let go of the eyelid and gently close the eyes. Do not blink. Keep the eyes closed for 1 or 2 minutes, to allow the medicine to come into contact with the infection.

If you think you did not get the drop of medicine into your eye properly, use another drop.

Avoid wearing contact lenses during treatment

To keep the medicine as germ-free as possible, do not touch the applicator tip to any surface (including the eye). Also, keep the container tightly closed.

For patients using the eye ointment form of this medicine:

First, wash your hands. Tilt the head back and with the index finger of one hand, press gently on the skin just beneath the lower eyelid and pull the lower eyelid away from the eye to make a space. Squeeze a thin strip of ointment into this space. A 1-cm (approximately ⅓-inch) strip of ointment is usually enough unless otherwise directed by your doctor. Let go of the eyelid and gently close the eyes and keep them closed for 1 or 2 minutes, to allow the medicine to come into contact with the infection.

To keep the medicine as germ-free as possible, do not touch the applicator tip to any surface (including the eye). After using gentamicin eye ointment, wipe the tip of the ointment tube with a clean tissue and keep the tube tightly closed.

To help clear up your infection completely, keep using this medicine for the full time of treatment, even if your symptoms have disappeared. Do not miss any doses.

Dosing

For ophthalmic ointment dosage form:
- For eye infections:
  - Adults and children—Use every eight to twelve hours.

For ophthalmic solution (eye drops) dosage form:
- For mild to moderate eye infections:
  - Adults and children—One to two drops every four hours.
- For severe eye infections:
  - Adults and children—One to two drops as often as once every hour as directed by your doctor.

Missed Dose

If you miss a dose of this medicine, apply it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.

Storage

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.

Keep out of the reach of children.

Do not keep outdated medicine or medicine no longer needed.

Precautions While Using Genoptic

If your symptoms do not improve within a few days, or if they become worse, check with your doctor.

Genoptic Side Effects

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur:

Less common

Itching, redness, swelling, or other sign of irritation not present before use of this medicine

redness of eye, eyelid, or inner lining of eyelid

Rare

Black, tarry stools; blood in urine or stools; or unusual bleeding or swelling

blurred vision, eye pain, sensitivity to light, and/or tearing

seeing, hearing, or feeling things that are not there

hallucinations

Less common

Burning or stinging

After application, eye ointments usually cause your vision to blur for a few minutes.

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: Genoptic side effects (in more detail)

More Genoptic resources

Genoptic Side Effects (in more detail)
Genoptic Use in Pregnancy & Breastfeeding
Genoptic Support Group
0 Reviews for Genoptic - Add your own review/rating

Genoptic Drops MedFacts Consumer Leaflet (Wolters Kluwer)

Genoptic Concise Consumer Information (Cerner Multum)

Garamycin Ophthalmic Concise Consumer Information (Cerner Multum)

Gentak Prescribing Information (FDA)

Gentak eent Monograph (AHFS DI)

Gentak Cream MedFacts Consumer Leaflet (Wolters Kluwer)

Compare Genoptic with other medications

Conjunctivitis, Bacterial

Friday, September 30, 2016

Ingredient matches for Adocef

Guaifenesin/Pseudoephedrine Controlled-Release Capsules are used for:

Do NOT use Guaifenesin/Pseudoephedrine Controlled-Release Capsules if:

Before using Guaifenesin/Pseudoephedrine Controlled-Release Capsules:

How to use Guaifenesin/Pseudoephedrine Controlled-Release Capsules:

Important safety information:

Possible side effects of Guaifenesin/Pseudoephedrine Controlled-Release Capsules:

If OVERDOSE is suspected:

General information:

More Guaifenesin/Pseudoephedrine resources

Compare Guaifenesin/Pseudoephedrine with other medications

Glynase Description

Glynase - Clinical Pharmacology

Actions

Pharmacokinetics

Indications and Usage for Glynase

Contraindications

SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY

Precautions

Macrovascular Outcomes

General

Hemolytic Anemia

Information for Patients

Physician Counseling Information for Patients

Laboratory Tests

Drug Interactions

Carcinogenesis, Mutagenesis, and Impairment of Fertility

Pregnancy

Pregnancy Category B

Nursing Mothers

Pediatric Use

Geriatric Use

Adverse Reactions

Overdosage

Glynase Dosage and Administration

Usual Starting Dose

Titration to Maintenance Dose

Concomitant Glyburide and Metformin Therapy

Maximum Dose

Dosage Interval

Specific Patient Populations

How is Glynase Supplied

PRINCIPAL DISPLAY PANEL - 1.5 mg - 100 Tablet Bottle

PRINCIPAL DISPLAY PANEL - 3 mg - 1000 Tablet Bottle

PRINCIPAL DISPLAY PANEL - 6 mg - 500 Tablet Bottle

More Glynase resources

Compare Glynase with other medications

Ingredient matches for Imuran

Commonly used brand name(s)

Uses For Gumsol

Before Using Gumsol

Allergies

Pediatric

Geriatric

Interactions with Medicines

Interactions with Food/Tobacco/Alcohol

Other Medical Problems

Proper Use of benzocaine

Dosing

Missed Dose

Storage

Precautions While Using Gumsol

Gumsol Side Effects

More Gumsol resources

Compare Gumsol with other medications

Thursday, September 29, 2016

Commonly used brand name(s)

Uses For Gly-Cort

Before Using Gly-Cort

Allergies

Pediatric

Geriatric

Interactions with Medicines

Interactions with Food/Tobacco/Alcohol

Other Medical Problems

Proper Use of hydrocortisone

Dosing

Missed Dose

Storage